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Propofol is the most commonly used sedative-hypnotic drug for noxious procedures, yet the molecular
targets underlying either its beneficial or toxic effects remain uncertain. In order to determine targets
andtherebymechanismsofpropofol,wehavesynthesizedaphotoactivateableanaloguebysubstituting
an alkyldiazirinyl moiety for one of the isopropyl arms but in the meta position. m-Azipropofol retains
the physical, biochemical, GABAA receptor modulatory, and in vivo activity of propofol and photo-
adducts to amino acid residues in known propofol binding sites in natural proteins. Using either mass
spectrometry or radiolabeling, this reagent may be used to reveal sites and targets that underlie the
mechanism of both the desirable and undesirable actions of this important clinical compound.
Introduction
Propofol (2,6-diisopropylphenol) is the most widely used
intravenous general anesthetic agent for induction and main-
tenanceofanesthesiaaswellassedationforproceduresandin
thecriticallyillpatient.
1Althoughmorepotentthantheinhaled
anesthetics,propofol’smicromolarEC50andlipophilicitystill
predict only brief interactions with its in vivo targets. This is
considered clinically useful because it allows for short dura-
tion of action once administration is stopped. Unfortunately,
these transient interactions make the molecular targets of
general anesthetics difficult tostudy. Theuse of photoaffinity
labeling has emerged as a promising technique for investigat-
ing these otherwise fleeting interactions.
2
A molecular target that is thought to contribute to propo-
fol’s ability to induce anesthesia is the GABAA
a receptor, a
ligand-gated chloride channel responsible for the majority of
inhibitory signaling in the brain. Propofol both activates
GABAA receptors and potentiates the activity of receptors
activated by GABA; these activities correlate with its in vivo
anesthetic potency.
3-5 However, the precise molecular inter-
actions between propofol and the GABAA receptor remain
unclear. Photoactive compounds that mimic propofol’s me-
chanism ofaction would allow a greater understandingof the
mechanisms.
Inaddition tostudiesdirectedatknownpropofol targets,a
propofol photoaffinity label could be used for identifying
other molecular targets of this drug, both desirable and un-
desirable. These studies would facilitate medicinal chemistry
aimed at favoringtargets underlyingeffects such asinduction
ofanesthesia,anticonvulsanteffects,andreductionofcerebral
bloodflowandmetabolicrate
1,6anddisfavoringthosetargets
underlying propofol’s toxicities. Most notable of these toxi-
cities would be respiratory depression and cardiac dysfunc-
tion, including bradycardia and hypotension,
7 and also EEG
activationandevenseizures.
8,9 Herewedescribe the synthesis
and characterization of a propofol analogue with an alkyl-
diazirinyl group in place of one of the isopropyl arms.
Results
Anobviouspositionforintroductionofaphotoactivatable
group into propofol would be as part of one of the existing
isopropyl groups in propofol itself. However, we recognized
that these positions, by virtue of being ortho to the phenolic
hydroxyl group, would likely lead to intramolecular reaction
of the active position withthe hydroxyl group rather than the
desired intermolecular reaction with proteins. Therefore, we
designed our propofol photoaffinity probe to contain the
photoactivatable group in a meta position relative to the
hydroxyl group. This design would preclude any intramole-
cular reaction of the reactive site with the phenolic hydroxyl
group.
Synthesis of m-Azipropofol (AziPm,1 ). Synthesis of 1 is
shownisScheme1.Cumene(2)istreatedwithbromineinthe
presence of a catalytic amount of iodine to give known
bromo compound 3, which is treated with magnesium fol-
lowed by N-trifluoroacetylpyrrolidine to give the previously
reported trifluoroacetylbenzene 4. Nitration conditions pro-
vide nitro compound 5, which is reduced under catalytic
hydrogenation conditions to give aniline 6. Conversion of 6
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to phenol 7 is accomplished using nitrous acid and boiling
aqueous acid. Subsequent protection of the free phenol group
using the tert-butyldimethylsilyl protecting group provides 8.
Introduction of the diazirine group into ketone 8 closely fol-
lowed a method previously described for a similar ketone.
10
Thus, conversion to oxime 9 and oxime tosylate 10 followed
standard procedures. Treating 10 with ammonia produces
diaziridine 11, which is oxidized with iodine and triethylamine
to produce diazirine 12. Deprotection of the tert-butyldi-
methylsilyl group occurs under standard fluoride conditions
to give 1 in an overall yield of 18% starting with cumene.
Physicochemical Properties. The physicochemical proper-
ties for both 1 and propofol are summarized in Table 1. The
octanol/waterpartitioncoefficientsof1(logP)andpropofol
werecalculatedtobe3.93and3.79,respectively.Densityof1
was determined to be 1.12 g/mL. The calculated molecular
dipole for 1 was 2.12 D, while the dipole for propofol, cal-
culated the same way, was 1.70 D. The UV absorption spec-
trum demonstrates a prominent diazirine peak at 368 nm
withanextinctioncoefficient(Σ368)of670/M.Becauseofthis
absorptionprofile,allphotolysiswasdonewitha350nmUV
lamp. The rate of disappearance of the diazirine during
irradiation in a cuvette, as measured by changes in the UV
spectrum, has a t1/2 of 34 min (95% CI=31-37 min). The
maximum concentration of 1 achievable in distilled water
was found to be 185 μM.
Binding Assays. Equilibrium binding of 1 to horse spleen
apoferritin (HSAF) was determined by two methods, ITC
andfluorescencecompetition,andtheresultsareprovidedin
Table2andinFigures1and2.Thereexistedgoodagreement
across methods and across the two compounds. Propofol
had a 2- to 4-fold higher affinity for HSAF than did 1. In the
photo-occlusion experiments, a 40% reduction in 1-AMA
fluorescence was noted when compared to control HSAF
samples that were identically treated but without the addi-
tion of 1 (Figure 3). Combined, these results support the
proposition that 1 binds the anesthetic pocket of HSAF
11
rather than inner filter effects explaining the competition
results.
In Vivo Anesthetic Potency. Both 1 and propofol showed
anesthetic activity in X. laevis tadpoles by reversibly extin-
guishing both spontaneous andelicited (startle reflex) move-
ment. The results of these assays are summarized in Table 3
and presented in Figure 4. The Hill slopes and EC50 values
for the two compounds had overlapping 95% confidence
intervals for all measurements, indicating similar potencies
in tadpoles. The only difference noted during the trials was
that propofol had more rapid kinetics; it reached its maxi-
mum effect in about half of the time that it took 1 to reach
steadystate.Also,itwas foundthatneithercompoundhada
concentrationthatimmobilized100%ofthetadpoles(lossof
startle response) reversibly. This suggested a very narrow
therapeutic ratio for both compounds, which was confirmed
to be less than 2. The EC50 reported here for propofol in
Xenopus tadpoles agrees with previously reported values,
despite subtle differences in methodology.
4
Electrophysiological Studies. We compared effects of pro-
pofol and 1 on R1β2γ2L GABAA receptors expressed in
HEK293 cells. At 0.3 and 3 μM, both compounds reversibly
enhanced responses of receptors activated by 3 μM GABA
(in fold changes, propofol 5.1 ( 3 and 9.3 ( 7.1; 1 1.8 ( 0.1
and 1.7 ( 0.4; p<0.05 for all). In addition, propofol but not
1directlyactivatedreceptors;i.e.,currentflowwasproduced
even in the absence of GABA. At the highest concentration
tested (30 μM), propofol strongly activated receptors. By
contrast, 30 μM 1 did not directly activate receptors, and
receptor activation in thecombined presence of30 μM 1 and
GABA was reduced or eliminated. However, upon removal
of 1 and GABA, there was a modest “rebound” or tail cur-
rent. This pattern of responses has been suggested to arise
from direct channel block by anesthetics.
12
Photolabeling.Inordertoconfirmtheabilityof1abilityto
act as a photolabel, HSAF was incubated in buffer with and
without saturated (185 μM) 1 and exposed to 350 nm illu-
mination for 20 min. Concentration and trypsinization were
followed by nano-LC/MS to identify peptides and residues
Scheme 1 Table 1. Physicochemical Properties
MW density, g/mL logP
a dipole,
a D HSAF KD, μM
1 244 1.12 3.93 2.12 19
propofol 178 0.96 3.79 1.70 10
aCalculated; see Experimental Procedures. logP = octanol/water
partition coefficient.
Table 2. Binding Parameters
1 propofol
ITC
fluorescence
competition ITC
fluorescence
competition
affinity
a 21 (20-22) 23 (17, 32) 4.8 (3.9-6.5) 12 (9, 15)
Hill slope 1
b -1.2
(-0.9, -1.6)
1
b -1.0
(-0.8, -1.2)
aMean (95% CI), in μM.
bData fitted to single class binding site,
so Hill slope fixed at 1.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 5669
thathadbeenmodifiedby216Da(1withoutthedinitrogen).
We detected peptides covering 42.9% of the apoferritin
sequence. The HSAF L chain demonstrated clear evidence
oftwoadductedpeptides.MS/MSsequencingindicatedthat
the adducts were located at leucine-81 and leucine-24, both
of which are known to be lining residues in the previously
identified propofol binding cavity (see Supporting Informa-
tion and Figure 6).
11
Discussion and Conclusions
In order to create a photolabel analogue of propofol, we
initially decided to incorporate an alkyldiazirine functional
group after the success of creating the smaller azi-isoflurane.
2
On the basis of previous investigations into the anesthetic
potency of various alkyl-substituted phenols,
13 we chose to
substitute the alkyldiazirine for one of the isopropyl groups
whileleaving theotherisopropylinthe2-positiononthering.
This decision produced the possibility of synthesizing a
series of azi-propofols, varying in which position on the ring
carried the diazirine group. While the ortho-azi-propofol
would demonstrate the greatest steric similarity to propofol,
the concern that the compound would internally rearrange
after diazirine decomposition instead of photolabeling made
this a less attractive initial objective. The rearrangement of
similar aromatic compounds into the corresponding ortho-
quinone methanides has been described.
14With this potential
for decomposition via an intramolecular pathway, we were
concerned about the effectiveness as a photolabel. Therefore,
Figure 2. Fluorescence competition with 1-aminoanthracene. Ti-
tration of the HSAF/1-AMA combination with either 1 (filled
symbols) or propofol (open symbols) produced inhibition of fluor-
escence consistent with competition for binding. Lines represent
nonlinear least-squares fits to variable slope Hill functions. Values
are given in Table 2.
Figure 1. Isothermal titration calorimetry of the HSAF interaction with either 1 (left) or propofol (right), using sequential titrations.
More sigmoid shaped curve with propofol indicates higher affinity, consistent with the values given in Table 2.
Figure 3. Photo-occlusion experiment. In order to confirm that
fluorescence competition was not due to inner filter or other
nonspecificinteractionsbetween1-AMA,1,andHSAF,theprotein
was photoadducted by 1/UV, washed, and then evaluated for
1-AMAbindingviafluorescenceenhancement.Thephotoadducted
sample had significantly reduced 1-AMA binding compared to the
UV control, consistent with adduction in the 1-AMA anesthetic
binding site.5670 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 Hall et al.
after ruling out the ortho compound and considering that
previously reported
13 structural analogues of the meta- and
para-compounds retained anesthetic potency, we chose to
synthesize the meta-compound 1 first.
Subsequent attempts to synthesize the para-azi-propofol
(AziPp) using the synthetic strategy outlined in Scheme 1
failedinthefinal,deprotectingstep.Wehypothesizedthatthis
occurred because the base-catalyzed deprotection creates a
phenoxideintermediate.Thephenoxideisconjugatedwiththe
diazirine in such a way that the diazirine decomposes imme-
diately;evolvedN2gaswasobservedduringtheadditionofthe
tetrabutylammonium fluoride. Attempts to synthesize AziPp
using a methoxymethyl protecting group, which is removed
under acid conditions, were only marginally more successful.
Any synthesized AziPp was seen to rapidly decompose when
isolation was attempted. Diazirines conjugated with phenols
are known to be very unstable under basic conditions,
15 and
withthisconjugationpotentiallyloweringthepKaofthemole-
cule below that of phenol, we expect there to be significant
decomposition and loss of photolabeling functionality when
AziPp is added to the pH 7.4 phosphate buffered saline in
which the HSAF experiments are performed. Hence, 1 was
synthesized as described herein.
Fromacomparisonof1topropofol,thediazirineexchange
for the isopropyl adds 66 Da to the molecular weight and in-
creases the dipole considerably, from 1.70 to 2.12 D, but still
makes the compound marginally more hydrophobic, with
logP changing from 3.79 to 3.93. Even with these changes, in
vitroandinvivobindingstudiesindicatethat1isahighlyana-
logous and similarly potent anesthetic when compared to
propofol.The1/HSAFinteractionwasfoundtobeofslightly
lower affinity compared to propofol/HSAF, but their EC50
values for anesthetizing tadpoles were not different. Both
compounds also enhanced agonist-stimulated activity of the
GABAA receptor complex at concentrations near those that
impaired movement ( < 3 μM), with 1 beingless potent. This is
consistent with previous work on propofol analogues where
loss of bulk from the 6-position or transfer of bulk from the
ortho to meta or para resulted in loss of potency.
4 It is of
interest that this lower potency at GABAA receptors is also
reflected in the HSAF affinity but not in the in vivo potency.
Previous work has shown that the relationship between
GABAA enhancement in heterologous expression systems
and tadpole immobilization only explains about half the
variation,
4soitispossiblethatadditionalmoleculartargetsof
propofol and 1 are contributing to immobilization in the
tadpole.
Alternatively, the ability of high concentration 1 to block
the GABAA complex (Figure 5) may indicate the recruitment
ofadditional,lowaffinitysiteswithinthisionchannelbecause
of the electrophysiological signature for channel blockade at
high (lethal) concentrations. Such a functionally antagonistic
site would be expected to reduce the coagonist actions of the
propofol site, as was observed. Finally, it is unlikely that
receptorblockadeunderlieslethality,sincebothpropofoland
1 were similarly lethal in tadpoles. Nevertheless, the ability of
1toblockreceptorsmayprovideanewtoolforunderstanding
theoriginofchannelblockathighconcentrations,afeatureof
other anesthetics.
12,16,17
The photolabeling experiment demonstrates that both 1
andpropofolarerecognized as similar by aproteinandthat1
hastheability toact asa photoaffinitylabel. Thecompetition
andocclusionstudieshadalreadysuggestedthat1bindsinthe
propofol-binding cavity of HSAF. The photolabeling experi-
ment identified that the 1 binding site was within labeling
distance of two residues, leucine-81 and leucine-24, which are
adjacent to each other and contribute to the lining of the pre-
viously identified propofol binding site of HSAF.
11 This con-
firms that 1 binds within the same cavity that propofol (and
inhaled anesthetics) binds, making this compound a promis-
ing photolabel for studies of propofol binding in other poten-
tialdrugtargets.Wecannotruleoutthatadductiontookplace
in 57% of the protein sequence for which peptides were not
identified, but we consider this unlikely because only a single
propofol site has been found with crystallography
11 and the
ITC and 1-AMA competition data for 1 are analogous to the
dataforpropofolandgivenoindicationofadditionalbinding
sites. The fact that affinity of the 1/HSAF interaction pre-
dicted the lowered efficacy for GABAA enhancement is fur-
ther evidence that the HSAF site bears strong architectural
andphysicochemicalsimilaritytothesiteunderlyingallosteric
enhancement in GABAA receptors.
Current application of 1 requires detection using mass
spectrometry. While this is useful for detecting adducted
peptides within proteins, it is less useful for detecting novel
targets in complex mixtures or anatomic regions of the brain
or heart that might have a high density of targets. Thus, a
future direction for this work involves incorporating a radio-
active moiety into 1. For example, [
3H]1 could be synthesized
by iodination of the aromatic ring followed by catalytic
Table 3. Tadpole Studies Results
1,
endpoint
propofol,
endpoint
spontaneous movement startle reflex spontaneous movement startle reflex
EC50
a (μM) 1.1 (0.9-1.4) 3.1 (2.7-3.5) 1.1 (0.9-1.3) 2.8 (2.6-3.0)
Hill slope 2.8 (1.6-4.0) 2.9 (1.7-4.1) 2.7 (1.6-3.9) 3.0 (2.4-3.7)
aValues in parentheses is the 95% confidence interval.
Figure 4. In vivo dose/response relationships. Tadpoles were eval-
uated with two end points: spontaneous (left set of curves, squares)
and elicited (right set of curves, circles) movement. Filled symbols
represent 1, and open symbols are propofol data. No significant
differences between the two drugs could be detected for either end
point.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 5671
hydrogenation to replace the iodine with tritium, using [
3H]2
gas as the source.
Experimental Procedures
Physicochemical Properties. The density of 1 was calcu-
latedfromtheslopeofthevolume/massrelationshipofthislow-
volatility compound. The UV spectrum and extinction coeffi-
cient of the diazirine absorption were first determined from
a methanolic solution of 1 of known concentration, and then
maximal water solubility was calculated from the extinction
coefficient. The rate of photolysis was determined from a 160 μM
solution in distilled water ina 1cm pathlength quartz cuvette in
contactwitha350nmUVlightfor30min,takingUVspectrato
monitor the disappearance of the diazirinyl peaks every 3 min.
Octanol/water partition coefficients were calculated using
XLOGP3.
18
Electronic structure calculations at the ab initio RHF/6-
31þG(d,p) geometry optimized level demonstrate two confor-
mations with 160 cal/mol difference as the lowest energy con-
formations.
19 These two conformations differ in rotation of
180 about the bond between the diazirine carbon and the aro-
matic ring such that the plane of the ring bisects the diazirine
double bond in both conformations. This indicates relatively
free rotation of the diazirine group relative to the aromatic ring.
The dipole moment calculated for each of these conformations
was found to be 1.99 and 2.25 D. With total energies so close,
we assumed that these conformations would contribute equally
tothetotaldipoleatroomtemperature,giving1adipoleof2.12D.
The same calculations for propofol demonstrated fairly free
rotation about bonds connecting each isopropyl group to the
aromatic ring, creating several minima with different individual
dipole moments. Consideration of a Maxwell-Boltzmann dis-
tribution for the total energy of each conformation at room
temperatureallowedthecalculationofanaveragedipoleof1.70
D, as the individual dipoles ranged between 1.67 and 1.80 D.
Binding Studies. Fluorescence Competition. The affinity of 1
forHSAFwasdeterminedbyaddingincreasing amountsof1to
a solution of HSAF and a constant amount of 1-aminoanthra-
cene (1-AMA).
20 All solutions were prepared in pH 7.4 phos-
phate buffered saline. In 500 μL quartz cuvettes, 7 μM HSAF
and 7 μM 1-AMA were combined with increasing concentra-
tions of 1 (0-110 μM). The fluorescence of 1-AMA in each of
these solutions was determined with 380 nm excitation while
monitoring emission between 400 and800 nm. The fluorescence
curves were corrected by subtracting the baseline fluorescence
curves of 1-AMA and HSAF. The fluorescence intensity vs
concentration data were fitted to variable slope Hill models to
obtaintheIC50andHillslope.TheKDwasthencalculatedusing
theCheng-PrusoffequationtocorrecttheIC50forthepresence
of the 1-AMA competitor.
20
Photo-Occlusion. To ensure that the measured effect of 1 on
the fluorescence of 1-AMA in HSAF was indeed caused by
competition for the anesthetic-binding pocket of HSAF rather
than an inner-filter effect of 1, a photo-occlusion experiment
Figure 5. Electrophysiology in GABAA receptors. Excised patches containing R1β2γ2L receptors were exposed to 3 μM GABA alone (left
column) or together with propofol (middle column) or 1 (right column) for 500 ms. At 0.3 and 3 μM, both compounds enhanced responses to
GABA. At a high concentration (30 μM), propofol directly activated channels, whereas 1 blocked channels.
Figure 6. AdductedHSAFresidues.ShownistheHSAFanesthetic
binding site with propofol bound (yellow), from PDB code 3F33.
Residues photolabeled by 1 (L24 and L81 from each of two
monomers) (pink) are immediately adjacent to propofol. Mass
spectra are provided in the Supporting Information.5672 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 Hall et al.
was performed. In 1 mL quartz cuvettes, 5 μM HSAF with or
without 140 μM 1 in pH 7.4 phosphate buffered saline was
irradiatedwith350nmlight(RayonetRPR-3500lamp)at2mm
distance for 20 min. Both samples were then passed through a
PD-10bufferexchangecolumntoremoveanyremainingsoluble
1 or unadducted photolysis products. HSAF solutions were re-
turned to the quartz cuvettes, and baseline fluorescence curves
wereobtainedforthe1sample,theirradiatedcontrol,andacon-
trol that had not been irradiated. There was no significant cha-
ngeinfluorescencebetweenthetwocontrols,indicatingalackof
appreciable UV damage to the HSAF. To each of the irradiated
HSAF samples was added 1-AMA (3 μM final concentration),
and fluorescence was recorded. Occlusion of the anesthetic
(1-AMA) binding site by adducted 1 is reflected by a significant
loss of fluorescence in the 1/UV sample.
Isothermal Titration Calorimetry. The thermodynamics of 1’s
interaction with HSAF was assessed by isothermal titration
calorimetryusing aMicrocal,Inc. VPITC(Northampton, MA;
http://www.microcalorimetry.com) and compared to that of
propofol. The ITC consists of a matched pair of sample and re-
ference vessels (1.43 mL) enclosed in an adiabatic enclosure and
arotatingstirrer-syringefortitratingaliquotsoftheligandsolu-
tion into the sample vessel. The sample cell contained 5 μM
HSAF,andthereference cellcontainedwater.Saturatedphoto-
label(185μM)wasloadedinthesyringe(volumeof0.28mL)for
injecting into the sample. Because of the low solubility of these
ligands,sequentialtitrationswereemployedtoachievesufficient
molar ratios for reliable model fitting, and these titrations were
linkedusingConCat32software(Microcal,Inc.,Northampton,
MA). In addition to these sequential titrations, control titra-
tions were performed, including ligand into buffer, buffer into
protein, and buffer into buffer, which were then used to correct
theexperimentaltitration,ligandintoprotein.Origin5.0(Microcal
Software, Inc., Northampton, MA) was used to fit thermo-
dynamic parameters to the heat profiles using a single binding
site class.
Tadpole Studies. In vivo activity studies were performed in
Xenopus tadpoles. Groups of 10 tadpoles were placed in 30 mL
of pond water containing various concentrations of 1 or propo-
fol. Tadpoles were incubated in the pond water with compound
for 30 min to allow for full equilibration, regardless of the
progress toward immobilization. At the end of the 30 min, the
anestheticeffectwasassessedusingtwoendpoints.Thefirstwas
loss of spontaneous motion, defined as the percentage of tad-
poles at each dose that did not swim, right themselves, or twitch
in a 30 s observation. The second end point was loss of elicited
movementtoasingle,sharptaponthelidoftheirdish.Tadpoles
that did not twitch or swim in response to this stimulus were
scored as anesthetized. The water in the dish was then replaced
with fresh pond water, and recovery was observed over the next
24 h.
Photolabeling. Small aliquots of pH 7.0 phosphate buffer
containing ∼5 μM HSAF with and without saturated (185 μM)
1 were placed in 300 μL, 1 mm path length quartz cuvettes and
exposed to 350 nm light (Rayonet RPR-3500 lamp) at < 2 mm
distance for 20 min. Control samples received only UV irradia-
tion. Samples were washed and concentrated with 50 kDa
centrifuge filters and then trypsinized and injected into a
nano-LC/MS (10 cm C18 capillary column) to separate and
identify the digested peptides. Eksigent NanoLC proteomics
experiments were run at 200 nL/min for 60 min with gradient
elution. Nanospray was used to spray the separated peptides
into LTQ (Thermo Electron). Xcalibur was used to acquire the
raw data, and modified (photolabeled) peptides were identified
usingSequest.Massspectrometryequipmentandsoftwarewere
available in the Proteomics Core Facility at the University of
Pennsylvania.
Electrophysiology. HEK293 Cell Culture and GABAA Recep-
tor Expression. HEK293 cells (CRL 1573, American Type Cul-
ture Collection) were maintained in standard culture conditions
(37C,5%CO2)inculturemediumconsistingofminimumessential
medium (MEM) with L-glutamine and Earle’s salts (Gibco), sup-
plemented with MEM amino acids solution (0.1 mM), sodium
pyruvate (1 mM), 1% penicillin/streptomycin, and 10% fetal
bovine serum (Harlan). For transfection, cDNAs for rat GA-
BAA receptor R1, β2, and γ2L subunits were subcloned into the
multiple cloning site of the mammalian expression vector
pUNIV.
21 For receptor expression, cells were plated onto 60 mm
culture dishes (Corning). After incubation for 24-48 h, cells
were co-transfected with rat R1β2γ2L (1:1:10) and 100 ng of
pCEP4-EGFP (Clontech) using Lipofectamine 2000 (Invitrogen),
then replated onto a 12 mm circle cover glass in 35 mm Petri
dishes (Falcon) 12-16 h after transfection. Transfected cells
were identified using a mercury arc lamp and a GFP filter cube
(Chroma Technology).
Electrophysiological Recordings. Recordings were performed
at room temperature on the stage of an inverted microscope.
Solutions were applied to excised outside-out patches or whole
cells using a custom-designed 12-barrel application system con-
structed of Teflon (28 gauge) and polyimide tubing (Cole-
Parmer).Thetubesweresealedtogetherandgluedontoamicro-
scopeslideusingUVcuringglue(Norlandopticaladhesive)and
secured in place using epoxy. The barrels were individually con-
nectedtosolutionreservoirs(10mL glasssyringes)usingTeflon
tubing and valves. The application system was mounted on a
motorized scanning stage (Corvus). An open-tip solution ex-
change time constant of 20-30 ms was typically achieved. The
recording chamber was perfused continuously with HEPES-
buffered saline containing the following (mM): NaCl 145, KCl
5, MgCl2 1, CaCl2 1.8 HEPES 10; pH 7.4. Recording electrodes
were fabricated from KG-33 glass (Garner Glass Company)
using a multistage puller (model P-87, Sutter Instruments). The
tips were fire-polished; open tip electrode resistance was typi-
cally 4-7M Ω when filled with standard recording solution.
Recording pipettes were filled with the following (mM): KCl
130, EGTA 5, HEPES 10, MgCl2 1, MgATP 5; pH 7.2. All
recordingswereobtainedataholdingpotentialof-40mVusing
an Axopatch 200A amplifier (Molecular Devices). GABA solu-
tionswerepreparedfreshdailyfrompowderandweredilutedto
the desired concentration (3 μM) in HEPES-buffered saline
solution. Propofol and 1 solutions were prepared by diluting
stock solutions containing 0.53 mM propofol and 0.18 mM azi-
propofol in HEPES-buffered saline solution.
Data Analysis. Ionic currents were analyzed using Clampfit
10 (MolecularDevices) and Origin 7.5(OriginLab, Northampton,
MA). Peak currents were measured relative to baseline and
normalized to the peak current elicited by a pulse of 3 μM
GABA. Data are presented as mean ( SD.
General Synthetic Procedures. All reagents and solvents were
used as received from commercial sources unless otherwise
noted.
1H,
13C, and
19F NMR spectra were recorded on a
Bruker DMX 360 MHz nuclear magnetic resonance spectro-
meter.
1H,
13C, and
19F NMR spectra are in the Supporting
Information. Determination of the final purity of 1 used capil-
lary GC (30m   0.25mm DB-5 column,135 Cinjector, 200 C
detector, column temperature of 100 C for 25 min, then 10 C/
min to 200 C) using flame ionization detection. Under these
conditions 1 has a retention time of ∼25 min and was shown to
be > 98% pure by integration.
2-Isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol(1).
To a round-bottom flask with a magnetic stir bar was added
466.8 mg (1.30 mmol) of 12 and 5 mL of dry THF. The solution
was cooled in an ice bath, and 1.45 mL (1.45 mmol) of TBAF
(1.0 M in THF) was added dropwise via syringe over 5 min. The
reaction mixture was allowed to warm and stir for 20 min at
room temperature. The mixture was poured into 20 mL of satu-
rated NH4Cl and extracted with methylene chloride. The or-
ganic layers were combined, washed with water, and dried with
Na2SO4. Solvent was removed under reduced pressure, and the
residue was purified on silica gel (20:1 hexanes/ethyl acetate).Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 5673
Evaporationofthesolventyielded279.1mg(88%)of1asapale-
yellow oil which was one spot by TLC.
1H NMR: δ 7.25 (d, J =
10.6 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 6.60 (bs, 1H), 4.97 (s,
1H),3.21(septet,J=6.9Hz,1H),1.25ppm(d,J=6.9Hz,6H).
19F NMR: δ -65.27 ppm.
13C NMR: δ 152.9, 136.5, 127.7,
127.1, 122.1 (q, J = 274 Hz), 119.1, 113.3, 28.2 (q, J = 40 Hz),
27.0,22.2ppm.UVspectrum:λmax=282,368nm.HRMS(ESI
neg): m/z calcd for C11H10F3N2O( M- H)
-, 243.0745; found,
243.0746.
1-Bromo-4-isopropylbenzene (3). A 500 mL round-bottom
flask with a magnetic stir bar was filled with 10.0 g (39.4 mmol)
of iodine crystals and 80.0 g (667 mmol) of isopropylbenzene.
The solution was cooled in an ice bath, and 110.0 g (688 mmol)
ofbrominewasaddedover15minwithgoodstirring.Asolution
of 60.0 g (1.07 mol) of potassium hydroxide in 200 mL of H2O
was added to the mixture. The reaction mixture was steam-
distilled for 12 h, with periodic addition of fresh water. The
organic layer of the distillate was dried over MgSO4 and then
distilledatatmosphericpressuretogive108.9g(82%)ofaclear,
colorless liquid, bp 217 C (lit. bp 216 C).
22 1H NMR: δ 7.44
(2H, d, J = 8.4 Hz), 7.13 (2H, d, J = 8.3), 2.85 (1H, septet),
1.27 ppm (6H, d, J = 6.9 Hz).
2,2,2-Trifluoro-1-(4-isopropylphenyl)ethanone (4). In a three-
neck round-bottom flask with a magnetic stir bar, 23.28 g (117
mmol)of3wasdissolvedin115mLofdryTHF.Tothissolution
was added 2.87 g (118 mmol) of magnesium metal. The reaction
vessel was fitted with a condenser topped with a nitrogen line
and an addition funnel containing 15.66 g (101 mmol) of 2,2,2-
trifluoro-1-pyrrolidin-1-ylethanone in 24 mL of dry THF. The
pot was heated slowly to reflux, and heating was continued for
20 min after the magnesium began to react to ensure complete
consumption of 3. The flask was cooled in an ice/salt bath for
25 min, during which time a fine, white precipitate formed. The
amide solution was added dropwise over 30 min at 0 C to the
well stirred solution. After the addition was complete, the ice/
salt bath was removed, and the mixture was stirred at room
temperature for 1 h. The reaction was quenched with 30 mL of
saturated aqueous NH4Cl solution and then vacuum-filtered to
leave a clear, golden liquid. After the mixture was dried over
MgSO4, solvent was removed under reduced pressure. Distilla-
tion under aspirator pressure yielded 16.20 g (74%) of 4,b p 13
95 C (lit. bp15 95 C).
23 1H NMR: δ 8.03 (2H, d, J = 7.6 Hz),
7.41 (2H, d, J = 7.7 Hz), 3.05 (1H, septet), 1.31 ppm (6H, d,
J = 6.9 Hz).
19F NMR: δ -71.73 ppm.
2,2,2-Trifluoro-1-(4-isopropyl-3-nitrophenyl)ethanone(5).Ina
beaker with a magnetic stir bar, an amount of 44.50 g of con-
centratedH2SO4wasaddeddropwiseto16.18g(74.9mmol)of4
at -10 C over 25 min, during which time a red precipitate
formed. While the temperature was maintained below -5 C, a
mixture of 10.84 g of concentrated HNO3 and 20.66 g of con-
centrated H2SO4 was added dropwise over 25 min. The ice/salt
bath was replaced with an ice/water bath, and the mixture was
allowed to stir for 1 h. The reaction mixture was poured onto
200goficeandwasextractedwithether(3 100mL).Theether
fractions were combined and washed with saturated aqueous
NaHCO3 until nomore CO2 wasgenerated. Theether layer was
dried over anhydrous MgSO4, and the solvent was removed
under reduced pressure. The resulting oil was distilled under
aspirator pressure to give 17.17 g (88%) of 5,b p 15 140 C.
1H
NMR:δ8.39(1H,s),8.23(1H,d),7.72(1H,d,J=8.4Hz),3.47
(1H, septet), 1.36 ppm (6H, d, J =6 . 8H z ) .
19FN M R :δ -72.39
ppm.
13CN M R :δ178.6 (q, J= 37 Hz), 150.3, 150.1, 133.0, 128.9,
128.4, 125.4, 116.4 (q, J= 289 Hz), 29.2, 23.1 ppm. HRMS (CIþ):
m/z calcd for C11H11NO3F3(Mþ H) 262.0691; found 262.0691.
1-(3-Amino-4-isopropylphenyl)-2,2,2-trifluoroethanone (6). A
round-bottom flask with a magnetic stir bar was filled with
26.50 g (101.5 mmol) of 5 dissolved in 160 mL of glacial acetic
acid. To this solution was added 68 mg of 30% Pt on asbestos
along with 511 mg of 10% activated Pd on carbon. The mix-
ture was stirred under a 1 atm hydrogen atmosphere at room
temperature for2days.Themixture wasfiltered throughCelite,
and the residue was rinsed with 95% ethanol. The combined
ethanol andaceticacid wereremoved underreduced pressureto
give6inquantitativeyield.
1HNMR:δ7.37(1H,s),7.49(1H,d,
J = 8.1 Hz), 7.30 (1H, d), 3.60 (2H, broad s), 2.95 (1H, septet),
1.31 ppm (6H, d, J = 6.8 Hz).
19F NMR: δ -71.49 ppm.
13C
NMR: δ 180.4 (q, J = 34 Hz), 144.2, 141.0, 128.3, 126.1, 120.9,
116.8(q,J=295Hz),116.1,28.1,21.7ppm.HRMS(CIþ):m/z
calcd for C11H13NOF3(M þ H
þ) 232.0949; found 232.0939.
2,2,2-Trifluoro-1-(3-hydroxy-4-isopropylphenyl)ethanone (7).
A large beaker with a magnetic stir bar and thermocouple was
filled with 20.44 g (88.4 mmol) of 6 and a solution of 31.0 mL of
concentrated H2SO4 and 24.0 mL of water. This mixture was
cooledto0C,andasolutionof9.16g(133mmol)ofNaNO2in
23.0 mL of H2O was added dropwise over the course of 90 min,
taking care to keep the temperature of the mixture below 4 C.
Once the addition was complete, this mixture was poured in
several small additions over 30 min through a condenser into a
round-bottom flask containing a refluxing solution of 68 mL of
concentrated H2SO4 and 90 mL of H2O. Additional water was
usedtorinseoutthebeaker.Oncetheadditionwascomplete,the
mixture was allowed to reflux for an additional 15 min before
being poured into 1 L of cold water, at which point a dark oil
separated. The mixture was extracted with ether, and the ether
was washed with water, dried over MgSO4, and removed at
reducedpressuretoleave16.14g(79%)ofcrude7.Thisblackoil
was taken to the next step without further purification. An
analytical sample was prepared by multiple sublimations under
reduced pressure, mp 58-60 C.
1H NMR: δ 7.64 (1H, d), 7.48
(1H,s),7.38(1H,d),3.35(1H,sep),1.31ppm(6H,d).
19FNMR:
δ -71.59 ppm.
13C NMR: δ 180.2 (q, J = 34 Hz), 153.4, 144.2,
128.4,127.2,123.4,116.7(q,J=295Hz),115.9,27.6,22.0ppm.
HRMS (CIþ):m/zcalcd for C11H11F3O2Na (M þ Na), 255.0609;
found, 255.0605.
1-[3-(tert-Butyldimethylsilanyloxy)-4-isopropylphenyl]-2,2,2-
trifluoroethanone (8). To a round-bottom flask with a magnetic
stirbarwasadded10.78g(46.4mmol)of7,250mLofdryTHF,
12.2 g (94.5 mmol) of diisopropylethylamine, and16.92 g (112.4
mmol) of tert-butyldimethylchlorosilane. This mixture was
stirredfor24hundernitrogenatmosphereatroomtemperature.
Themixturewaspouredinto500mL ofH2Oandextractedwith
methylene chloride. The combined organic phase was washed
with water, and volatiles were removed under vacuum. Crude 8
was purified through a short column of silica, eluting with pure
hexanestogive7.62g(47%)of8asanoil.
1HNMR:δ7.67(1H,
bd), 7.50 (1H,bs),7.38 (1H,d,J =8 Hz),3.40 (1H,septet), 1.25
(6H, d, J = 7 Hz), 1.06 ppm (9H, s).
19F NMR: δ -71.2 (s).
13C
NMR: δ 179.8 (q, J = 34 Hz), 153.3, 148.4, 128.3, 126.9, 123.4,
118.9, 116.9 (q, J = 290 Hz), 27.2, 25.7, 22.2, 18.2 ppm. HRMS-
(CIþ): m/z calcd for C17H26F3O2Si (M
þ), 347.1654; found,
347.1653.
1-[3-(tert-Butyldimethylsilanyloxy)-4-isopropylphenyl]-2,2,2-
trifluoroethanone Oxime (9). To a round-bottom flask with a
magnetic stir barwas added 6.87g (19.8mmol) of8,1.75 g(25.2
mmol)ofhydroxylaminehydrochloride,and50mLofpyridine.
Themixturewasheatedinanoilbathto60Candstirredfor4h
under nitrogen atmosphere. Volatiles were then removed under
vacuum. The remaining crude product was partitioned between
methylene chloride and water, and the organic phase was
subsequently washed with water. Solvent was removed under
vacuum to leave 6.82 g (95%) of 9 as an approximately 1:1 mix-
ture of oxime diastereomers as determined by NMR. The crude
product was taken to the next step without further purification.
Ananalyticalsamplewaspreparedbyflashchromatographyon
silica gel (10:1 hexanes/ethyl acetate, Rf ≈ 0.3).
1H NMR: δ 9.4
(1H,bs),7.32(0.6H, d,J=8Hz),7.27(0.4H, d,J=8Hz),7.18
(0.6H, bd), 7.09 (0.4H, bd), 7.06 (0.6H, bs), 6.93 (0.4H, bs), 3.37
(1H, m), 1.24(6H, m), 1.06 (9H, s), 0.28 ppm (6H,s).
19F NMR:
δ -62.3 (1F, s), -66.3 ppm (1.2F, s).
13C NMR: δ 152.8, 152.7,
147.8, 147.4, 147.3, 147.0, 142.2, 142.0, 127.8, 126.5, 126.4,5674 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 Hall et al.
123.5, 122.3, 121.6, 120.0, 119.2, 118.5, 118.0, 116.9, 26.8, 26.7,
25.8, 25.7, 22.6, 22.5, 18.2, -4.2, -4.3 ppm. HRMS(CIþ): m/z
calcd for C17H27F3NO2Si (M
þ), 362.1763; found 362.1780.
1-[3-(tert-Butyldimethylsilanyloxy)-4-isopropylphenyl]-2,2,2-
trifluoroethanone Oxime Tosylate (10). A round-bottom flask
with a magnetic stir bar was filled with 5.75 g (15.9 mmol) of 9
and 110 mL of methylene chloride. To this stirred solution was
added 93 mg (0.76 mmol) of 4-(N,N-dimethylamino)pyridine,
3.18 g (16.7 mmol) of p-toluenesulfonyl chloride, and 2.20 g
(21.8mmol)oftriethylamine.Themixturewasstirredfor24h
under nitrogen atmosphere at room temperature. The reaction
mixture was then partitioned between water and methylene chlo-
ride, and the organic phase was subsequently washed with addi-
tionalwater.Volatileswereremovedundervacuumtoleave7.50g
(91%) of crude 10 as a 2:3 mixture of diastereomers as deter-
mined by NMR. This crude product was taken to the next step
withoutfurtherpurification.Ananalyticalsamplewasprepared
by flash chromatography on silica gel (20:1 hexanes/ethyl ace-
tate) and was followed by TLC in 10:1 hexanes/ethyl acetate,
Rf=0.4,togive10asathickgum.
1HNMR:δ7.95(2H,m),7.4
(2H, m), 7.32 (0.6H, d), 7.28 (0.4H, d), 7.07 (1H, m), 6.97 (0.6H,
m),6.91(0.4H,m),3.38(1H,m),2.47(3H,m),1.24(3H,m),1.07
(9H,m), 0.31 (3.4H, s), 0.26 ppm (2.6H, s)
19F NMR: δ -61.2
(2F), -66.1 ppm (3F).
13C NMR: δ 153.5, 153.2, 152.9, 152.8,
146.1, 145.9, 143.8, 143.6, 131.7, 131.4, 129.9, 129.8, 129.1, 126.8,
126.7,125.6,122.2,121.8,119.1,118.5,115.9,31.6,26.8,26.8,25.7,
22.6, 22.4, 21.65, 18.3, 18.2, 14.0, -4.3 ppm. HRMS(CIþ): m/z
calcd for C24H33F3NO4SSi (M þ H
þ), 516.1852; found 516.1835.
3-[3-(tert-Butyldimethylsilanyloxy)-4-isopropylphenyl]-3-tri-
fluoromethyldiaziridine (11). A solution of 7.50 g (14.5 mmol) of
10 dissolved in 15.0 g of diethyl ether was added to excess liquid
ammonia at -78 C and stirred vigorously as it was allowed to
come to room temperature over the course of 5 h. More ether
was added to the reaction mixture, and the combined organic
phase was washed with water. The ether solution was dried over
Na2SO4, and solvent was removed under reduced pressure to
leave5.13g(98%)ofcrude11.Thecrudeproductcouldbetaken
to the next step without further purification. An analytical sam-
ple was prepared by flash column chromatography (hexanes/
ethyl acetate = 20:1) followed by TLC in the same solvent sys-
tem with an Rf of 0.25 to give 11 as a thick oil.
1H NMR: δ 7.26
(1H,d, J= 6.6Hz),7.20(1H, d,J= 6.6Hz),7.065 (1H,s), 3.34
(1H, m, J = 5.7 Hz), 2.75 (1H, broad s), 2.20 (1H, broad d, J =
5.7Hz),1.24(6H,d),1.06(9H,s),0.28ppm(6H,s).
19FNMR:δ
-75.43 ppm.
13C NMR: δ 152.78, 141.25, 129.60, 128.17,
126.56, 123.5 (q, J = 278 Hz), 120.45, 117.78, 57.66 (q, J =
36 Hz), 26.61, 25.74, 25.73, 22.64, 22.61, 18.25, -4.22, -4.27 ppm.
HRMS (CIþ): m/z calcd for C17H28F3N2OSi (M
þ), 361.1923;
found, 361.1926.
3-[3-(tert-Butyldimethylsilanyloxy)-4-isopropylphenyl]-3-tri-
fluoromethyl-3H-diazirine (12). A round-bottom flask with a
magnetic stir bar was filled with 5.35 g (14.8 mmol) of crude 11,
40 mL of methylene chloride, and 5.8 g (22.9 mmol) of iodine.
Themixturewascooledinanicebath,and4.57g(45.2mmol)of
triethylamine was added dropwise. The ice bath was removed,
and the mixture was allowed to stir at room temperature for
45min.Itwaspouredinto650mLof1MNaOHandwasstirred
vigorously for 15 min. The mixture was extracted with methyl-
ene chloride. The organic layer was washed with water and eva-
porated under reduced pressure. The resultant crude product
was flushed through a short column of silica with pure hexanes
togive3.10g(58%)of12asayellowoil.
1HNMR:δ7.22(1H,d,
J=8.1Hz),6.70(1H,s),6.63(1H,d,J=8.1Hz),3.30(1H,sep,
J=6.9Hz),1.19(6H,d,J=6.9Hz),1.04(9H,s),0.27ppm(6H,
s).
19F NMR: δ -65.67 ppm.
13C NMR: δ 153.1, 141.1, 127.2,
126.8, 122.2 (q, J = 275 Hz), 118.9, 116.4, 28.2 (q, J=40 Hz),
26.6, 25.7, 22.5 18.2, -4.3 ppm. HRMS(CIþ): m/z calcd for
C17H26F3N2OSi (M
þ), 359.1767; found, 359.1762. The column
was then flushed with an equal volume of 10:1 hexanes/ethyl
acetate to recover 1.78 g of unreacted 11.
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